SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-057481
Filing Date
2023-11-01
Accepted
2023-11-01 16:23:56
Documents
14
Period of Report
2023-11-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K prld-20231101.htm   iXBRL 8-K 56735
2 EX-99.1 prld-ex99_1.htm EX-99.1 197449
3 GRAPHIC img268059179_0.jpg GRAPHIC 5700
  Complete submission text file 0000950170-23-057481.txt   400705

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prld-20231101.xsd EX-101.SCH 2465
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prld-20231101_lab.xml EX-101.LAB 17761
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prld-20231101_pre.xml EX-101.PRE 11109
8 EXTRACTED XBRL INSTANCE DOCUMENT prld-20231101_htm.xml XML 4717
Mailing Address 200 POWDER MILL ROAD WILMINGTON DE 19803
Business Address 200 POWDER MILL ROAD WILMINGTON DE 19803 (302) 547-3768
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

IRS No.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39527 | Film No.: 231368592
SIC: 2834 Pharmaceutical Preparations